Oricell leverages a proprietary technology triad—Ori®Ab antibody discovery, Ori®Armoring T-cell enhancement, and OnGo CMC rapid manufacturing—to develop a diversified pipeline of cell therapies targeting solid tumors and hematologic malignancies. Its lead asset, Ori-C101, is a GPC3-targeted autologous CAR-T for advanced hepatocellular carcinoma that has completed investigator-initiated trials and a registrational Phase 1 and is preparing for pivotal trials, with clinical readouts highlighted at major forums including ASCO. Another core candidate, OriCAR-017, advanced from IIT in China to global development, securing IND approvals from China NMPA and the US FDA as well as FDA Orphan Drug and Fast Track designations. Oricell has presented data at multiple global conferences (including ASCO and EHA) and published results in The Lancet Haematology. The company states the programs have demonstrated favorable safety and robust efficacy in IIT and registrational trials, supporting its global regulatory and clinical strategy.

Total raised

$345M

Funding rounds

4

Latest round

Equity

Latest activity

Apr 2026